Hansa On a High After CHMP Thumbs-Up For Idefirix
Positive Opinion For Kidney Transplant Drug
Executive Summary
Sweden's Hansa Biopharma has taken an important step closer to becoming a commercial-stage company with the backing of European regulators for Idefirix, although launch plans have been impacted by the COVID-19 crisis.
You may also be interested in...
Vertex's Triple CF Combo Gets EU Approval Nod; Rejection For Daiichi Sankyo
EU approval is likely for the eight medicines that got the thumbs up this week from the European Medicines Agency's drug evaluation committee, the CHMP. The panel held fire on one product it had been considering and also issued its first rejection of 2020.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
C4XD Delisting Highlights Funding Frustration For UK Biotechs
The Manchester-based group has had enough of being undervalued in the public markets and is going private again.